Antimicrobial Resistance in Human Health, Crisis, and Seizing Opportunities: A Comprehensive Literature Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Antimicrobial resistance (AMR) poses a significant threat to global health, with the potential to reverse decades of medical progress. AMR occurs when microorganisms evolve to resist the effects of antimicrobial drugs, rendering treatments ineffective. This phenomenon is driven by mechanisms such as genetic mutations, horizontal gene transfer, and the overuse of antimicrobials in both human medicine and agriculture. The economic impact of AMR is profound, with projections indicating a potential reduction in global gross domestic product by 2% to 3.5% by 2050, disproportionately affecting low- and middle-income countries (LMICs) due to weaker healthcare infrastructure and higher rates of infectious diseases. Addressing AMR requires a multifaceted approach, including improved antimicrobial stewardship, enhanced surveillance, and the development of new treatments. Surveillance systems, particularly in LMICs, are often inadequate, highlighting the need for global collaboration and data-sharing networks like the Latin American Antimicrobial Resistance Surveillance Network (ReLAVRA). Additionally, the interconnected use of antimicrobials in humans, animals, and the environment necessitates a One Health approach to effectively combat AMR. Preventive measures such as vaccination, infection control practices, and rapid diagnostic tests are crucial in reducing the spread of resistant infections. Antimicrobial stewardship programs and precision medicine offer promising strategies to minimize unnecessary antimicrobial use and slow resistance development. However, the development of new antimicrobials remains a critical challenge, requiring innovative models of collaboration between academia, industry, and governments.
Abstract
Antimicrobial resistance (AMR) poses a significant threat to global health, with the potential to reverse decades of medical progress. AMR occurs when microorganisms evolve to resist the effects of antimicrobial drugs, rendering treatments ineffective. This phenomenon is driven by mechanisms such as genetic mutations, horizontal gene transfer, and the overuse of antimicrobials in both human medicine and agriculture. The economic impact of AMR is profound, with projections indicating a potential reduction in global gross domestic product by 2% to 3.5% by 2050, disproportionately affecting low- and middle-income countries (LMICs) due to weaker healthcare infrastructure and higher rates of infectious diseases. Addressing AMR requires a multifaceted approach, including improved antimicrobial stewardship, enhanced surveillance, and the development of new treatments. Surveillance systems, particularly in LMICs, are often inadequate, highlighting the need for global collaboration and data-sharing networks like the Latin American Antimicrobial Resistance Surveillance Network (ReLAVRA). Additionally, the interconnected use of antimicrobials in humans, animals, and the environment necessitates a One Health approach to effectively combat AMR. Preventive measures such as vaccination, infection control practices, and rapid diagnostic tests are crucial in reducing the spread of resistant infections. Antimicrobial stewardship programs and precision medicine offer promising strategies to minimize unnecessary antimicrobial use and slow resistance development. However, the development of new antimicrobials remains a critical challenge, requiring innovative models of collaboration between academia, industry, and governments.